- Home
- » Tags
- » Candida auris
Top View
- Fungal INFECTIONS Fungi Are Everywhere
- Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and After Lung Transplantation
- Candida Auris
- Drug Repurposing Strategies in the Discovery of Antifungal Agents
- A New Culture Medium for the Isolation of All Candida Auris Clades
- Antifungal Drug Repurposing
- Candida Auris Outbreaks, Colombia [Announcer] This Program Is Presented by the Centers for Disease Control and Prevention
- Epidemiological Alert
- Candida Auris and Emerging Resistant Organisms
- Epidemiology of Emerging Fungal Infections in ICU
- Candida Auris Health Advisory
- Descriptions of Medical Fungi
- Integrated Transcriptional Analysis of the Cellular and Extracellular Vesicle
- British Yeast Group: Discovery to Impact 26–28 June 2019 County Hotel, Newcastle, UK POSTER ABSTRACT BOOK
- Overview of Candida Auris and Emerging Resistant Candida
- PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections
- Article, Mary Brandt and Benjamin Park Note the Growing Number of Human Infections from Traditional and New Fungal Agents
- Candida Auris Fact Sheet
- Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps
- Antifungal Effects of PC945, a Novel Inhaled Triazole, on Candida Albicans Pulmonary Infection in Immunocompromised Mice
- (P) and Potentially Pathogenic (PP) Bacteria/Yeast
- Application of Probiotic Yeasts on Candida Species Associated Infection
- ESCMID† and ECMM‡ Joint Clinical Guidelines for the Diagnosis And
- Antifungal Activity of a Medical-Grade Honey Formulation Against Candida Auris
- Den170081 Summary
- Nine Things Genomics Can Tell Us About Candida Auris
- Rare Fungal Infectious Agents: a Lurking Enemy [Version 1; Peer Review: 4 Approved] Anna Skiada 1, Ioannis Pavleas2, Maria Drogari-Apiranthitou3
- Trichosporon Asahii Patients with Malignant • Trichosporon Asteroides • Trichosporon Cutaneum Haematological Disease
- Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants
- Candida Auris: an Overview of How to Screen, Detect, Test and Control This Emerging Pathogen
- Antifungal Resistance and Candida Auris Infections
- Candida Auris, an Emerging Drug-Resistant Yeast Responsible for Healthcare Outbreaks
- Candida Auris (C
- Tracking Candida in Oregon
- Candida Auris Infection Control Challenges
- Top Papers in Diagnostics/Laboratory
- Candida: the Unfriendly Yeast NHS.UK
- Drug-Resistant Candida Auris Threat Level Urgent
- Amphotericin B and Other Polyenes—Discovery, Clinical Use, Mode of Action and Drug Resistance
- Fungal Infections in Immunocompromised Hosts
- Novel Fungal Treatments in Development
- Candida Auris: a Drug-Resistant Fungus That Spreads in Healthcare Facilities a CDC Message to Infection Preventionists
- Genetic Susceptibility to Fungal Infections and Links to Human Ancestry
- High Mortality Co-Infections of COVID-19 Patients: Mucormycosis and Other Fungal Infections
- Candida Auris Informational Session
- Comparison Between MALDI-TOF MS and Microscan in the Identification
- Integrated Genomic, Epidemiologic Investigation of Candida Auris Skin Colonization in a Skilled Nursing Facility
- Fungal Surveillance: Candida Auris and Mold
- Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens